Form 4: Monopar Therapeutics Director Lavina Talukdar Reports Stock Option Grant
SEC Form 4 Filing
Director Lavina Talukdar reports the acquisition of stock options in Monopar Therapeutics.
Summary
- Lavina Talukdar, a director of Monopar Therapeutics, filed a Form 4 disclosing a transaction.
- The transaction involved the acquisition of 5,683 stock options with an exercise price of $31.70 on March 4, 2025.
- These options vest 25% quarterly starting March 31, 2025, and expire on March 4, 2035.
- Following the transaction, Talukdar directly owns 5,683 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the sentiment is neutral.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction (stock option grant) |
| 03/31/2025 | First vesting date for the stock options (25%) |
| 06/30/2025 | Second vesting date for the stock options (25%) |
| 09/30/2025 | Third vesting date for the stock options (25%) |
| 12/31/2025 | Fourth vesting date for the stock options (25%) |
| 03/04/2035 | Expiration date of the stock options |
| 03/07/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.